This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacobus, N. V.
Right arrow Articles by Snydman, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobus, N. V.
Right arrow Articles by Snydman, D. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2004, p. 1034-1036, Vol. 48, No. 3
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.3.1034-1036.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Tigecycline against the Bacteroides fragilis Group

N. V. Jacobus,1 L. A. McDermott,1 R. Ruthazer,2 and D. R. Snydman1*

Division of Geographic Medicine and Infectious Diseases, Department of Medicine,1 Division of Clinical Research, Tufts-New England Medical Center, Boston, Massachusetts 021112

Received 19 May 2003/ Returned for modification 9 August 2003/ Accepted 9 November 2003

The in vitro activities of tigecycline were tested against 831 isolates of the Bacteroides fragilis group representing all of the species within the group. On a weight-to-weight basis (8 µg/ml), tigecycline was more active than clindamycin, minocycline, trovafloxacin, and cefoxitin and less active than imipenem or piperacillin-tazobactam against all isolates of the B. fragilis group. Tigecycline geometric mean MICs were statistically higher against B. distasonis than other Bacteroides species (P value of 0.0001).

* Corresponding author. Mailing address: Division of Geographic Medicine and Infectious Diseases, Tufts-New England Medical Center, Boston, MA 02111. Phone: (617) 636-5788. Fax: (617) 636-8525. E-mail: dsnydman{at}tufts-nemc.org.

Antimicrobial Agents and Chemotherapy, March 2004, p. 1034-1036, Vol. 48, No. 3
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.3.1034-1036.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Karageorgopoulos, D. E., Kelesidis, T., Kelesidis, I., Falagas, M. E. (2008). Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 62: 45-55 [Abstract] [Full Text]  
  • Betriu, C., Culebras, E., Gomez, M., Lopez, F., Rodriguez-Avial, I., Picazo, J. J. (2008). Resistance Trends of the Bacteroides fragilis Group over a 10-Year Period, 1997 to 2006, in Madrid, Spain. Antimicrob. Agents Chemother. 52: 2686-2690 [Abstract] [Full Text]  
  • Nord, C. E., Sillerstrom, E., Wahlund, E. (2006). Effect of tigecycline on normal oropharyngeal and intestinal microflora.. Antimicrob. Agents Chemother. 50: 3375-3380 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y. A., Tyrrell, K. L., Fernandez, H. T. (2006). Comparative In Vitro Susceptibilities of 396 Unusual Anaerobic Strains to Tigecycline and Eight Other Antimicrobial Agents. Antimicrob. Agents Chemother. 50: 3507-3513 [Abstract] [Full Text]  
  • Kasbekar, N. (2006). Tigecycline: A new glycylcycline antimicrobial agent.. Am J Health Syst Pharm 63: 1235-1243 [Abstract] [Full Text]  
  • Livermore, D. M. (2005). Tigecycline: what is it, and where should it be used?. J Antimicrob Chemother 56: 611-614 [Abstract] [Full Text]  
  • Bradford, P. A., Petersen, P. J., Young, M., Jones, C. H., Tischler, M., O'Connell, J. (2005). Tigecycline MIC Testing by Broth Dilution Requires Use of Fresh Medium or Addition of the Biocatalytic Oxygen-Reducing Reagent Oxyrase To Standardize the Test Method. Antimicrob. Agents Chemother. 49: 3903-3909 [Abstract] [Full Text]  
  • Pankey, G. A. (2005). Tigecycline. J Antimicrob Chemother 56: 470-480 [Abstract] [Full Text]  
  • Betriu, C., Culebras, E., Gomez, M., Rodriguez-Avial, I., Picazo, J. J. (2005). In vitro activity of tigecycline against Bacteroides species. J Antimicrob Chemother 56: 349-352 [Abstract] [Full Text]  
  • Pachon-Ibanez, M. E., Jimenez-Mejias, M. E., Pichardo, C., Llanos, A. C., Pachon, J. (2004). Activity of Tigecycline (GAR-936) against Acinetobacter baumannii Strains, Including Those Resistant to Imipenem. Antimicrob. Agents Chemother. 48: 4479-4481 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»